早期HBcrAg与抗-HBc水平识别核苷(酸)类似物停药后严重发作高风险患者——两项临床试验的汇总分析
两项在荷兰和加拿大开展的前瞻性研究汇总分析,纳入78例符合EASL标准停用核苷(酸)类似物的患者,检测治疗结束时和随访第6周的HBcrAg与抗-HBc水平。结果显示,治疗结束时HBcrAg较高、抗-HBc较低及HBcrAg/抗-HBc比值较高与严重发作风险增加相关,随访第6周也观察到类似关联。
要点
- 治疗结束时HBcrAg≥4log患者严重发作率47%,高于<3log患者的19%(p=0.036)。
- 治疗结束时抗-HBc<2log患者严重发作率50%,高于≥3log患者的11%(p=0.029)。
- 治疗结束时HBcrAg/抗-HBc比值≥2患者严重发作率58%,高于<1.5患者的14%(p<0.001)。
核心结论
- 治疗结束时及停药后最初数周内HBcrAg较高、抗-HBc较低及HBcrAg/抗-HBc比值较高与核苷(酸)类似物停药后肝脏发作风险增加相关,可能有助于筛选适合停药的患者及识别需要再治疗的患者。
研究设计与样本
- 研究为两项在荷兰和加拿大开展的前瞻性研究的汇总分析,患者依据EASL标准入组,共分析78例患者。
主要发现
- 平均年龄49岁,16例(21%)为白人,65%接受替诺福韦治疗。
- 22例(28%)发生严重发作,29例(37%)接受再治疗。
- 治疗结束时HBcrAg较高(aOR 1.97,p=0.05;≥4log:47% vs <3log:19%,p=0.036)、抗-HBc较低(aOR 0.29,p=0.036;<2log:50% vs ≥3log:11%,p=0.029)及HBcrAg/抗-HBc比值较高(aOR 3.17,p=0.015;≥2:58% vs <1.5:14%,p<0.001)与严重发作风险增加相关,校正HBsAg。
- 随访第6周HBcrAg较高(aOR 2.91,p=0.035;≥5log:83%,<3log:4%,p<0.001)、抗-HBc较低(aOR 0.46,p=0.29;<2log:50% vs ≥3log:0%,p=0.003)及HBcrAg/抗-HBc比值较高(aOR 2.19,p=0.048;≥1.75:52% vs <1.75:8%,p<0.001)与严重发作风险增加相关,校正HBV DNA和ALT。
临床怎么用
- 作者认为,治疗结束时及停药后最初数周内HBcrAg较高、抗-HBc较低及HBcrAg/抗-HBc比值较高可能用于筛选适合停药的患者及识别需要再治疗的患者。
局限性
- 本研究为两项既往注册临床试验的事后分析和随访研究,未前瞻性纳入新患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Severe flares (ALT ≥ 10×ULN) are a well-recognised adverse outcome after nucleos(t)ide analogue (NA) cessation and may lead to liver failure. Thus, identification of patients at risk for these flares is of major importance. METHODS: Data were used from two prospective studies on NA cessation conducted in the Netherlands and Canada. Patients were eligible based on EASL criteria. HBcrAg and anti-HBc levels were measured at end of treatment (EOT) and week 6 (FUW6). Logistic regression was used to study the association with severe flares. RESULTS: Seventy-eight patients were analysed with a mean age of 49 years, 16 (21%) Caucasian and a majority (65%) were treated with Tenofovir. Overall, 22 patients (28%) developed a severe flare, and 29 (37%) patients were retreated. At EOT, higher HBcrAg levels (aOR: 1.97, p = 0.05; ≥ 4log: 47% severe flare vs. < 3log: 19%, p = 0.036), lower anti-HBc (aOR: 0.29, p = 0.036; < 2log: 50% vs. ≥ 3log: 11%, p = 0.029) and higher HBcrAg/anti-HBc-ratio (aOR: 3.17, p = 0.015; ≥ 2: 58% vs. < 1.5: 14%, p < 0.001) were associated with an increased risk of severe flares, adjusted for HBsAg. At FUW6, higher HBcrAg (aOR: 2.91, p = 0.035; ≥ 5log: 83%, < 3log: 4%, p < 0.001), lower anti-HBc (aOR: 0.46, p = 0.29; < 2log: 50% vs. ≥ 3log: 0%, p = 0.003) and higher HBcrAg/anti-HBc-ratio (aOR: 2.19, p = 0.048; ≥ 1.75: 52% vs. < 1.75: 8%, p < 0.001) were associated with an increased risk of severe flares, adjusted for HBV DNA and ALT. CONCLUSION: Higher HBcrAg, lower anti-HBc and higher HBcrAg/anti-HBc ratio at EOT and during the first weeks of post-treatment follow-up are associated with an increased risk of hepatic flares after NA withdrawal and could therefore potentially be used to select patients eligible for therapy cessation and to identify patients requiring retreatment. TRIAL REGISTRATION: This study was a post hoc and follow-up study of two previously registered clinical trials (NCT01911156 & NTR7001). No new patients were prospectively included.
引用
- Dongelmans EJ, Feld JJ, Boonstra A, et al. Early HBcrAg and Anti-HBc Levels Identify Patients at High Risk for Severe Flares After Nucleos(t)ide Analogue Cessation-A Pooled Analysis of Two Clinical Trials. Aliment Pharmacol Ther. 2024. PMID: 39624922. doi:10.1111/apt.18416
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。